TABLE 5.

Comparison of pharmacokinetics/pharmacodynamics and efficacy of ciprofloxacin in the neutropenic rat thigh infection model with data from humans

Species	Total dose (regimen)a	Value (range)				Efficacy (% microbiological cure)
		AUC24 (μg·h/mL)	AUC24/MIC	Cmax (μg/mL)	Cmax/MIC
Humansb	400 mg (7 mg/kg − 200 mg, b.i.d., i.v.)	49 (9.0–229)	802 (6.2–5,541)	4.8 (1.9–15.4)	100 (0.9–769)	88% clinical cure (81)
Rat (human-equivalent dose)c	50 mg/kg (u.i.d.)d	40	81–1,290	34	69–1,102	≥3 log10 CFU/g thigh reduction (99)
	50 mg/kg (25 mg/kg, b.i.d.)d	40	81–1,290	19	38–604	≥3 log10 CFU/g thigh reduction (99)
	90 mg/kg (u.i.d.)e	73	146–2,342	59	119–1,900	≥3 log10 CFU/g thigh reduction (99)
	90 mg/kg (45 mg/kg, b.i.d.)e	73	146–2,342	31	62–992	≥3 log10 CFU/g thigh reduction (99)

^ab.i.d., twice a day; u.i.d., once a day.

^bHuman data are from reference 7.

^cSee Materials and Methods for calculations.

^dRat equivalent of a human total dose of 400 mg (7).

^eRat equivalent of a human total dose of 800 mg (21).